BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Driving the Robustness of Preclinical Research within the Pharmace
 utical Industry - Katrina Gore\, formerly of Pfizer Neusentis
DTSTART:20161011T181500Z
DTEND:20161011T203000Z
UID:TALK61533@talks.cam.ac.uk
CONTACT:Peter Watson
DESCRIPTION:In the past few years it has been hard to pick up a copy of Na
 ture\, Science or many preclinical biomedical research journals without se
 eing an article on the issue of non-reproducible research.  They all ackno
 wledge that research is plagued by findings that are not reliable and just
  cannot be reproduced.  The pharmaceutical industry is not immune to these
  issues. Replication of published research findings is a key component of 
 drug target identification and provides confidence to progress internal dr
 ug projects into the discovery pipeline.  We also use data from internal a
 ssays to assess the biological and pharmacokinetic activity\, selectivity 
 and safety of novel compounds and make decisions which impact their progre
 ssion towards clinical development. Many pharmaceutical companies have sta
 tisticians engaging with research scientists however the ratio of statisti
 cians to scientists is typically low.  This talk will describe the role of
  a preclinical statistician\, outline the key challenges they face and foc
 us on how Pfizer is implementing the Assay Capability Tool.  The ACT was c
 reated by Research Statistics within Pfizer to guide the development of dr
 ug discovery assays and to address issues of robustness and reproducibilit
 y in research.  It promotes easy to follow but absolutely essential experi
 mental design strategies and represents the distilled experience of the pr
 ovision of over three decades of statistical support to laboratory scienti
 sts.
LOCATION:MRC Cognition and Brain Sciences Unit
END:VEVENT
END:VCALENDAR